QQQ $ 628.93 $ 10.99 (1.78 %)
DIA $ 475.40 $ 3.14 (0.66 %)
SPY $ 685.52 $ 7.99 (1.18 %)
TLT $ 91.88 $ 0.31 (0.34 %)
GLD $ 367.78 $ -10.51 (-2.78 %)
$ 0.883
-- x --
-- x --
-- - --
$ 0.81 - $ 1.07
28,718
na
10.76M
nm
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-15-2025 03-31-2025 10-Q
2 02-27-2025 12-31-2024 10-K
3 11-14-2024 09-30-2024 10-Q
4 08-08-2024 06-30-2024 10-Q
5 05-09-2024 03-31-2024 10-Q
6 03-22-2024 12-31-2023 10-K
7 11-09-2023 09-30-2023 10-Q
8 08-10-2023 06-30-2023 10-Q
9 05-11-2023 03-31-2023 10-Q
10 03-15-2023 12-31-2022 10-K
11 11-14-2022 09-30-2022 10-Q
12 08-11-2022 06-30-2022 10-Q
13 05-16-2022 03-31-2022 10-Q
14 03-24-2022 12-31-2021 10-K
15 11-10-2021 09-30-2021 10-Q
16 08-12-2021 06-30-2021 10-Q
17 05-12-2021 03-31-2021 10-Q
18 03-18-2021 12-31-2020 10-K
19 11-12-2020 09-30-2020 10-Q
20 08-13-2020 06-30-2020 10-Q
21 05-14-2020 03-31-2020 10-Q
22 03-19-2020 12-31-2019 10-K
23 11-12-2019 09-30-2019 10-Q
24 08-12-2019 06-30-2019 10-Q
25 05-20-2019 03-31-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hookipa-pharma-q1-eps-123-misses-062-estimate-sales-200m-miss-338m-estimate

HOOKIPA Pharma (NASDAQ:HOOK) reported quarterly losses of $(1.23) per share which missed the analyst consensus estimate of $(0....

 hookipa-pharmas-board-has-determined-that-it-does-not-intend-to-make-an-offer-for-poolbeg

- Reuters 

 hc-wainwright--co-downgrades-hookipa-pharma-to-neutral

HC Wainwright & Co. analyst Arthur He downgrades HOOKIPA Pharma (NASDAQ:HOOK) from Buy to Neutral.

 deal-dispatch-vera-bradley-is-a-mixed-bag-modells-ex-ceo-explores-party-city

Vera Bradley faces shareholder pressure for underperformance, while acquisitions and restructurings define this week's deal...

 rbc-capital-downgrades-hookipa-pharma-to-sector-perform-lowers-price-target-to-2

RBC Capital analyst Brian Abrahams downgrades HOOKIPA Pharma (NASDAQ:HOOK) from Outperform to Sector Perform and lowers the ...

 jmp-securities-maintains-market-outperform-on-hookipa-pharma-lowers-price-target-to-7

JMP Securities analyst Roy Buchanan maintains HOOKIPA Pharma (NASDAQ:HOOK) with a Market Outperform and lowers the price tar...

 rbc-capital-maintains-outperform-on-hookipa-pharma-lowers-price-target-to-48

RBC Capital analyst Brian Abrahams maintains HOOKIPA Pharma (NASDAQ:HOOK) with a Outperform and lowers the price target from...

 hookipa-pharma-q3-2024-gaap-eps-110-beats-128-estimate-sales-4703m-miss-6250m-estimate

HOOKIPA Pharma (NASDAQ:HOOK) reported quarterly losses of $(1.10) per share which beat the analyst consensus estimate of $(1.28...

 hookipa-pharma-presented-updated-phase-2-data-from-a-study-evaluating-eseba-vec-in-combination-with-pembrolizumab-as-front-line-therapy-in-the-setting-of-human-papillomavirus-type-16-positive-relapsed-or-metastatic-head-and-neck-squamous-cell-carcinoma-at-sitc-2024

HOOKIPA Pharma Inc. (NASDAQ:HOOK, "HOOKIPA", the "Company"))), a clinical-stage biopharmaceutical company devel...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION